Dr. Dalia Rotstein is an assistant professor of medicine at the University of Toronto and neurologist specialized in multiple sclerosis (MS) and other demyelinating diseases. She completed neurology residency at University of Toronto where she was co-chief resident and MS fellowship at the Brigham and Women’s Hospital/Harvard University, where she also earned a Master of Public Health degree.
Her research is focused on the epidemiology of multiple sclerosis and neuromyelitis optica spectrum disorder (NMOSD). She has a particular interest in the roles of gender, ethnicity, migration, and vitamin D in these conditions. She has performed foundational work to validate No Evidence of Disease Activity (NEDA) as an early treatment goal on MS therapy. She is the Principal Investigator for CANOPTICS, the first Canadian national prospective study to investigate adults with NMOSD, MOG Antibody Disease, and other atypical demyelinating conditions.
Dr. Rotstein founded the NMOSD Multi-Disciplinary Clinic at St. Michael’s Hospital in 2020 and the international educational program NIRVE, the Neurology International Residents Videoconferencing Exchange, in 2009. She now serves as the faculty mentor for NIRVE and enjoys mentoring students, residents and fellows. She is an associate editor for the journal Frontiers in Neurology.
